EDIT vs SNPS · rev $32.3M vs P/E 63, rev $7.05B
Editas Medicine Inc (EDIT) versus Synopsys Inc (SNPS) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Synopsys Inc (SNPS) is a software - infrastructure company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported SNPS revenue for 2025-10-31 was $7.05B. Net income was $1.33B. Revenue was up 15.1% from 2024-10-31 to 2025-10-31. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
EDIT currently screens at market cap $375.2M. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
Not investment advice. Open the EDIT and SNPS stock pages for the full models.
Not investment advice.